Table 1 Demographic and patients characteristics
From: Haloperidol prophylaxis in critically ill patients with a high risk for delirium
| Â | Control group (N= 299) | Intervention group (N= 177) | Differences (P-value) |
|---|---|---|---|
Male (n/%) | 181 (61%) | 115 (65%) | 0.20 |
Age | 64 ± 14 | 63 ± 14 | 0.64 |
APACHE-II score | 20 ± 7 | 19 ± 6 | 0.06 |
Urgent admission (%) | 261 (87%) | 152 (86%) | 0.52 |
Sedation level (RASS, median (IQR)) - RASS screening compliance (%) | -1 (-3 to 0) 93.3 ± 1.2 | -1 (-3 to 0) 94.5 ± 0.9 | 0.84 |
Haloperidol administering | Â | Â | Â |
   - Number of treated patients (%) | 225 (75.3%) | 177 (100%) | <0.0001 |
   - Number of treated days | 5 (2 to 12) | 5 (3 to 11)* | 0.23 |
   - Dosage (mg per day) median ((IQR)) | 6 (3 to 10) | 2 (2 to 3) | <0.0001 |
Sepsis (N/%) | 64 (21%) | 53 (30%) | 0.02 |
Admission specialism (N/%): | Â | Â | Â |
   - Surgical | 75 (25%) | 33 (19%) | 0.18 |
   - Medical | 143 (48%) | 106 (60%) | 0.12 |
   - Trauma | 32 (11%) | 18 (10%) | 0.27 |
   - Neurology/neurosurgical | 49 (16%) | 20 (11%) | 0.36 |
PRE-DELIRIC score | 73 ± 22 | 75 ± 19 | 0.50 |
Other risk | Â | Â | Â |
   - Alcohol abuse | 41 (14%) | 20 (11%) | 0.37 |
   - Dementia | 5 (2%) | 2 (1%) |  |